Celgene/Acceleron win speedy FDA review for luspatercept in beta thalassemia; Korean investor out to shake up Aurinia's board
→ As hoped, Celgene $CELG and its partners at Acceleron $XLRN have secured priority review for their red blood cell boosting drug, luspatercept, which …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
